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INTRODUCTION 
TUBERCULOSIS: 
Tuberculosis is a chronic granulomatous disease which is a major health 
problem in developing countries. About one third of the world’s population is infected 
with Mycobacterium tuberculosis. As per WHO, 9 million people suffer from TB and 1.7 
million die annually because of TB. In India, every year nearly 2 million people develop 
this disease and about 0.5 million die and is a leading cause of death from an infectious 
disease worldwide, after the human immunodeficiency virus (HIV)1. Co- infection with 
the HIV fuels the global TB crisis, and successful TB treatment is further complicated 
and hampered by the existence of multidrug- resistant (MDR) TB and extensively drug 
resistant (XDR) TB2. 
 
 
 
 
 
Fig. 1: Mycobacterium tuberculosis3 
An estimated 13.7 million chronic cases were active globally, while in 2013, an 
estimated 9 million new cases occurred. In 2013 there were between 1.3 and 1.5 million 
associated deaths, most of which occurred in developing countries. The total number of 
tuberculosis cases has been decreasing since 2006, and new cases have decreased since 
2002. Many people in the developing world contract tuberculosis because of a poor 
immune system, largely due to high rates of HIV infection and the corresponding 
development of AIDS4. 
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HISTORY: 
Mycobacterium originated more than 150 million years ago. The German 
microbiologist Robert Koch in 1882 conformed the rod shaped organism caused TB. The 
discovery of the Bacillus-Calmette Guerin (BCG) vaccine in 1908 and anti-tuberculosis 
drugs starting in 1943, offered hope for the eradication of this disease5. 
Mortality rates decreased significantly from the early to mid-20th century. The 
Directly Observed Treatment Short-Course (DOTS) program was introduced in 1993. In 
1998 the DOTS-plus program was introduced to address multidrug resistant  (MDR) TB6. 
The Food and Drug Administration (FDA), on 28 December 2012, granted 
accelerated approval to SIRTURO™ (bedaquiline) Tablets as a part of combination 
therapy in adults with multidrug- resistant TB (MDR-TB). It is the first new anti-TB drug 
to be approved after 1998 (rifapentine was approved in 1998) and the first anti-TB drug 
with a novel mechanism of action to be approved after 40 years (rifampicin was approved 
in 1974). It is also the first to be introduced specifically for the treatment of MDR-TB in 
combination with other drugs7. 
TYPES OF TUBERCULOSIS: 
Tuberculosis is a contagious disease; it affects almost all the important organs 
of the body and are generally considered to be, 
1.Pulmonary tuberculosis,  2.Extra pulmonary tuberculosis 
PULMONARY TUBERCULOSIS8 : 
Pulmonary tuberculosis (TB) is when M. tuberculosis primarily attacks the 
lungs. However, it can spread from there to other organs. Pulmonary TB is curable with 
an early diagnosis and antibiotic treatment. 
Pulmonary TB, also known as consumption, spread widely as an epidemic 
during the 18th and 19th centuries in North America and Europe. After streptomycin, an 
antibiotic, was discovered in 1944, people were able to treat and control the spread of TB. 
Since then, TB has been in decline. It’s at its lowest recorded rate since 1953. 
The upper lung lobes are more frequently affected by tuberculosis than 
the lower ones. The reason for this difference is not entirely clear. It may be due 
either to better air flow, or to poor lymph drainage within the upper lungs. 
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EXTRAPULMONARY TUBERCULOSIS9: 
Tuberculosis (TB) outside the lung usually results from hematogenous 
dissemination. Sometimes infection directly extends from an adjacent organ. These are 
Miliary TB, Genitourinary TB, TB meningitis, TB peritonitis, TB pericarditis, TB 
lymphadenitis, TB of bones and joints, Gastrointestinal TB, TB of the liver and other 
sites. Symptoms vary by site but generally include fever, malaise, and weight loss. 
Diagnosis is most often by sputum smear and culture and, increasingly, by rapid 
molecular-based diagnostic tests. Treatment is with multiple antimicrobial drugs given 
for at least 6 months. 
 
TREATMENT 10,11: 
TB can usually be cured. More than twenty drugs have been developed 
for treating TB. But most of the drugs were developed many years ago. The treatment 
usually consists of a combination of TB drugs that must be taken for at least six months. 
But the treatment will only be successful if the drugs are taken exactly as required for the 
entire length of time. The drugs are used in different combinations in different 
circumstances. For example, the five “first line” drugs are given to people who have 
never had treatment before. 
Some of the drugs have very severe side effects and are very difficult to take for 
such a long period of time. This is why there is an urgent need for new TB drugs to be 
developed. In addition many people are now resistant to one or more of the drugs. 
 
DRUG RESISTANT TB12: 
If someone has drug resistant TB it means that the bacteria in their body won’t 
be affected by certain drugs that they are resistant to. The drugs just won’t work. There 
are two main reasons why people develop it. It can be because the person doesn’t take 
their drugs properly. It can also be that the bacteria that they are infected with, have come 
from someone who has already got drug resistant TB. Being drug sensitive is the opposite 
of being drug resistant. 
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If someone has drug resistant TB then they must change drugs. But usually they 
mustn’t have just one new drug. They need to have several new drugs and for it to be 
believed that they will all be effective. Drug susceptibility testing which is available in 
many countries, and is very important, provides information about which drugs a person 
is resistant to. 
Multi Drug-Resistant Tuberculosis (MDR TB) is caused by organism resistant 
to both Isoniazid and Rifampicin which are the most effective anti Tb drug13. 
Extensively Drug-Resistant Tuberculosis (XDR TB) is a relatively rare type of 
drug resistant TB, which is resistant to both Isoniazid and Rifampicin, plus any other 
Fluoroquinolone and at least one of three injectable second line14. 
Totally Drug–Resistant Tuberculosis (TDR-TB) in which the TB strains that 
showed in-vitro resistance to all first and second line drugs tested (isoniazid, rifampicin, 
streptomycin, ethambutol, pyrazinamide, ethionamide, para-aminosalicylic acid, 
cycloserine, ofloxacin, amikacin, ciprofloxacin, capreomycin, kanamycin)15. 
MYCOBACTERIA16: 
Mycobacterium tuberculosis has an unusual, waxy coating on its cell surface 
(primarily due to the presence of mycolic acid), which makes the cell impervious to gram 
staining. Mycobacterium tuberculosis is the rod-shaped, spore forming aerobic bacterium.  
Mycobacterium tuberculosis and seven very closely related mycobacterium 
species (M. bovis, M. africanum, M. microti, M. caprae, M. pinnipedii, M. canetti and M. 
mungi) are together known as M. tuberculosis complex. 
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SCIENTIFIC CLASSIFICATION16: 
Kingdom  : Bacteria. 
Phylum  : Actinobacteria. 
Class  : Actinobacteria. 
Order  : Actinomycetales. 
Suborder : Corynebacterineae. 
Family  : Mycobacteriaceae. 
Genus      : Mycobacterium. 
Species         : Mycobacterium tuberculosis. 
Synonym      : Tubercle bacillus Koch 1882. 
 
CELL WALL STRUCTURE17,18: 
The cell wall is composed of two segments, upper and lower. Beyond the 
membrane is peptidoglycan (PG) in covalent attachment to arabinogalactan (AG), which 
in turn is attached to the mycolic acids with their long meromycolate and short alpha-
chains. This is termed the cell wall core-the mycolyl arabinogalactan–peptidoglycan 
(mAGP) complex. The upper segment is composed of free lipids, some with longer fatty 
acids complementing the shorter alpha-chains, and some with shorter fatty acids 
complementing the longer chains.  
Interspersed within are the cell-wall proteins, the phosphatidyl Inositol 
Mannosides (PIMs), the phthiocerol containing lipids, lipomannan (LM), and 
lipoarabinomannan (LAM). When cell walls are disrupted, for instance extracted with 
various solvents, the free lipids, proteins, LAM, and PIMs are solubilized, and the 
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mycolic acid–arabinogalactan–peptidoglycan complex remains as the insoluble residue. 
In simplistic terms, it can be considered that these lipids, proteins, and lipoglycans are the 
signaling, effector molecules in the disease process, whereas the insoluble core is 
essential for the viability of the cell and should be addressed in the context of new drug 
development. 
The importance of understanding the biosynthesis of the mycolic acid–
peptidoglycan–arabinogalactan complex is more in the context of new drug development 
against tuberculosis (TB) and less in defining the bacterial factors responsible for the 
disease process. 
This peptidoglycan, which forms the backbone of the mAGP, consists of 
alternating units of N-acetylglucosamine and N-glycolylmuramic acid. 
The arabinogalactan polymer is comprised exclusively of D-galactofuranoses 
and D-arabinofuranoses which are extremely rare in nature. The polysaccharide is also 
unusual in that, unlike many bacterial polysaccharides, it is composed not of repeating 
units but a few distinct, defined structural motifs. 
Mycolic acids are large, alpha-alkyl branched, and beta-hydroxylated fatty 
acids. Two families of mycolic acids are known: a mycolates without any oxygenated 
functional groups and the oxygenated mycolates. 
 Slow growing pathogenic mycobacteria such as M. tuberculosis modify their 
acids by cyclopropanation, whereas rapid growing saprophyte species such as M. 
smegmatis do not. The mycolic acids also occur within the fluid matrix in the form of 
free trehalose dimycolate (TDM) (‘cord factor’) and trehalose monomycolate (TMM); 
both of these components are distributed on the cell surface. TMM is regarded as a 
precursor of the arabinan-linked mycolates, and TDM has been implicated in the 
pathogenesis of tuberculosis. 
The other dominant feature of the mycobacterial cell wall is the LAM which is 
somewhat embedded into the framework of the mAGP. 
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Fig. 2: Cell wall structure of Mycobacterium tuberculosis17 
GENOME: 
Mycobacterium tuberculosis encodes about 190 transcriptional regulators: 13 σ 
factors, 11 two-component systems, 5 unpaired response regulators, 11 protein kinases, 
and more than 140 other putative transcriptional regulators. Several of these regulators 
have been characterized; some of them respond to environmental stresses such as cold 
shock, heat shock, hypoxia, iron starvation, surface stress, and oxidative stress, while 
others respond to still unknown environmental conditions19. 
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Mycobacterium tuberculosis has circular chromosomes of about 4,200,000 long 
nucleotide. The genome was studied generally using the strain Mycobacterium 
tuberculosis H37Rv. The genome has about 4000 genes. Genes that code for lipid 
metabolism are very important part of the bacterial genome and 8% of the genome is 
involved in its activity19. 
 
                                                                                                                                                                                               
 
 
 
 
Fig. 3: Genome of Mycobacterium tuberculosis20 
 
MODE OF TRANSMISSION21: 
TB is usually spread through cough, sneeze, speak, sing, or spit, they expel 
infectious aerosol droplets 0.5 to 5.0µm in diameter. A single sneeze can release up to 
40,000 droplets. They transmit the disease, since the infectious dose of tuberculosis is 
small. 
The probability of transmission from one person to another depends upon the 
several factors including duration of exposure, effectiveness of ventilation, the virulence 
of M. tuberculosis strain, the level of immunity of uninfected person. 
If someone does become infected, it typically takes three to four weeks before 
the newly infected person becomes infectious enough to transmit the disease to others.  
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PATHOPHYSIOLOGY 22: 
Mycobacterium tuberculosis is classified as acid- fast gram- positive bacteria 
due to their lack of an outer cell membrane. It divides every 15-20 hours. Which is 
extremely slow compared to other bacteria, it is a small bacilli that can withstand weak 
disinfectants and can survive in a dry state for weeks. 
 
 
 
 
Fig. 4: Pathophysiology of Tuberculosis23 
NEED TO FOCUS ON TUBERCULOSIS DISEASE24: 
 
 Tuberculosis is a leading cause of death worldwide. 
 In the year 2000-2005, there were around 10 to 15 million people with 
latent TB in the U.S & in 2007, 2.4 million cases were reported. 
 In the year 2010, WHO estimated that one-third of the world’s population 
(two billion people) was infected with the bacilli. Of the two billion people, 
approximately 9.8 million people will develop active tuberculosis and 2.6 million people 
will die per annum. 
 In the year 2013, approximately 13.7 million chronic active cases  were 
globally detected in the year 2014, approximately 560 thousand new cases per year and 
740 thousand new patients infected by both MTB and HIV due to multidrug-resistant 
Tuberculosis. 
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NEED FOR NEW ANTI-TB DRUGS25: 
 To improve the treatment of MDR-TB. 
 To improve current treatment by shortening the total duration of the 
treatment. 
 To counter the new resistant form of TB. 
  To design new drugs that are more active against slowly growing and non 
growing persistent bacilli. 
 To discover compounds that would reduce both the length of treatment 
and the frequency of drug administration. 
 To provide more effective treatment for latent tuberculosis infection. 
ENZYME PROFILE26,27: 
GLUTAMINE SYNTHETASE I 
Antibiotics typically target key cell wall or intracellular molecules of 
microorganisms that are involved in cell wall, protein, or DNA synthesis, or in an 
essential metabolic pathway. On the basis of studies in this report, we shall propose an 
additional site for antibiotic targeting: extracellular enzymes released by a bacterium. 
M . tuberculosis , along with other pathogenic mycobacteria, is unusual among 
bacterial species in that it secretes or otherwise releases a large number of proteins in 
considerable quantities into its extracellular milieu. Such extracellular proteins are 
released by M. tuberculosis organisms when growing either in broth medium or 
intraphagosomally in human mononuclear phagocytes, the bacterium’s primary host 
cells. Approximately 100 proteins are released into broth medium by M. tuberculosis, 11 
of which are released in great abundance.  
One of the abundantly released proteins is the enzyme glutamine synthetase, 
which is surprising because this enzyme is typically located in the bacterial cytoplasm. 
Even more surprising, only pathogenic mycobacteria such as M. tuberculosis and M. 
bovis release large amounts of glutamine synthetase extracellularly, whereas 
nonpathogenic mycobacteria, such as M. smegmatis and M. phlei, and nonmycobacterial 
microorganisms, such as Legionella pneumophila and Escherichia coli, do not. 
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Glutamine synthetase is an enzyme that plays an essential role in the 
metabolism of nitrogen by catalyzing the condensation of glutamate and ammonia to 
form glutamine: 
Glutamate + ATP + NH3 → Glutamine + ADP + phosphate 
 
Glutamine synthetase (GS; EC 6.3.1.2, also known as γ-glutamyl: ammonia 
Ligase) catalyzes the adenosine 5´-triphosphate (ATP) dependent condensation between 
glutamate and ammonia, to give glutamine. There are three types of GS, each with a 
different structure. These enzymes are present in all organisms; eukaryotes express GS 
type II while prokaryotes mainly express GS types I and III. 
The release of Glutamine synthetase by pathogenic mycobacteria is correlated 
with the presence of a polyl -glutamate/glutamine component in the cell walls of these 
organisms; nonpathogenic mycobacteria lack this component . This suggests the 
possibility that extracellular glutamine synthetase is involved in the synthesis of polyl -
glutamate/glutamine and that the enzyme’s extracellular presence is significant to 
virulence. 
In this report, we shall demonstrate that an irreversible inhibitor of M. 
tuberculosis extracellular glutamine synthetase blocks bacterial multiplication both in 
broth medium and in human mononuclear phagocytes and that growth inhibition is 
correlated with a marked reduction in the amount of the virulence-associated cell wall 
component polyl -glutamate/glutamine.  
Remarkably, the enzyme inhibitor has no effect against nonpathogenic 
mycobacteria, which do not export glutamine synthetase. Although the inhibitor of 
glutamine synthetase may target additional extracellular proteins, our report provides 
strong evidence for the concept that targeting extracellular proteins of pathogenic 
mycobacteria and perhaps other pathogens is a feasible strategy for developing new 
antibiotics. 
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Fig. 5: Glutamine synthetase Enzyme having 5 chains28 
 
MECHANISM27: 
Glutamine synthetase catalyzes the ATP dependent condensation of glutamate 
with ammonia to yield glutamine. The hydrolysis of ATP drives the first step of a two 
part, concerted mechanism. ATP phosphorylates glutamate to form ADP and an acyl 
phosphate intermediate, γ-glutamyl phosphate, which reacts with ammonia, forming 
glutamine and inorganic phosphate. ADP and Pi do not dissociate until ammonia binds 
and glutamine is released. ATP binds first to the top of the active site, glutamate binds 
near the second cation binding site at the bottom of the active site. The presence of ADP 
causes a conformational shift in GS that stabilizes the γ-glutamyl phosphate moiety. 
Ammonium binds strongly to GS only if the acylphosphate intermediate is present. 
Ammonium, rather than ammonia, binds to GS because the binding site is polar and 
exposed to solvent. In the second step, deprotonation of ammonium allows ammonia to 
attack the intermediate from its nearby site to form glutamine. Phosphate leaves through 
the top of the active site, while glutamine leaves through the bottom (between two rings). 
DRUG DESIGN29: 
Drug discovery process involves a rapid search for a small molecule often 
called as lead. A lead molecule is chemical compound which possess pharmacological or 
biological activity. Sources of lead compounds can come from natural sources, such as 
plants, animals, or fungi and also from synthetic chemical libraries. 
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LEAD IDENTIFICATION/OPTIMIZATION30,31: 
Lead identification/optimization is the one of the most important steps in drug 
development. The chemical structure of the lead compound is used as a starting point for 
chemical modifications in order to improve potency, selectivity, or pharmacokinetic 
parameters. 
RATIONAL DRUG DESIGN32: 
A. Development of small molecules with desired properties for targets, biomolecules 
(proteins or nucleic acids), whose functional roles in cellular processes and 3D 
structural information are known. This approach in drug design is well established 
and is being applied extensively by the pharmaceutical industries. 
B. Development of small molecules with predefined properties for targets, whose 
cellular functions and their structural information may be known or unknown. 
Knowledge of unknown targets (genes and proteins) can be obtained by analyzing 
global gene expression data of samples untreated and treated with a drug using 
advanced computational tools. 
Once a target is identified, then both approaches (A) and (B) for development of 
small molecules require examination of several aspects. These aspects include, but are 
not limited to, the evaluation of binding scores (affinity/specificity), balance between 
hydrophilicity/lipophilicity, absorption, distribution, metabolism, and excretion (ADME), 
electrophilic, nucleophilic, and radical attack (biodegradation), toxicity of the parent 
small molecules, and products due to biotransformation in the different phases of 
metabolism, quantitative structure–activity relationship (QSAR), and quantitative 
structure–property relationship (QSPR) respectively. Most of these aspects including 
design of a small molecule could be performed initially using computational tools. 
COMPUTER AIDED DRUG DESIGN33: 
The most fundamental goal in drug design is to predict whether a given 
molecule will bind to a target and if so how strongly. Molecular mechanics or molecular 
dynamics is most often used to estimate the strength of the intermolecular interaction 
between the small molecule and its biological target.  
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Drug design with the help of computers may be used at any of the following 
stages of drug discovery: 
1. Hit identification using virtual screening (structure- or ligand-based design). 
2. Hit-to-Lead optimization of affinity and selectivity (structure-based design, 
QSAR, etc.). 
3. Lead optimization of other pharmaceutical properties while maintaining affinity. 
In order to overcome the insufficient prediction of binding affinity calculated by 
recent scoring functions, the protein-ligand interaction and compound 3D structure 
information are used for analysis. 
TYPES OF DRUG DESIGN: 
There are two major types of drug design.  
1. Ligand- Based Drug Design and  
2. Structure-Based Drug Design. 
LIGAND BASED DRUG DESIGN34: 
Ligand-based drug design is one of the popular approaches for drug discovery 
and lead optimization. 3D structure-activity relationships (3D QSAR) and 
pharmacophore modeling are the most important and widely used tools in ligand-based 
drug design that can provide crucial insights into the nature of the interactions between 
drug target and ligand molecule and provide predictive models suitable for lead 
compound optimization. 
STRUCTURE BASED DRUG DESIGN35,36: 
Structure-based drug design is most powerful when it is a part of an entire drug 
lead discovery process. structure-based design can lead to the parallel synthesis of 
focused compound libraries. It is also important to consider that structure- based drug 
design directs the discovery of a drug lead, which is not a drug product but, specifically, a 
compound with at least micromolar affinity for a target. Binding site identification is the 
first step in structure based design. If the structure of the target or a sufficiently similar 
homolog is determined in the presence of a bound ligand, then the ligand should be 
observable in the structure in which case location of the binding site is trivial. 
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SCREENING AND DESIGN34,35: 
The process of finding a new small molecule [ligand] against a chosen target for 
a particular disease usually involves high-throughput screening [HTS]. 
The structure – activity relationship [SAR] is to improve certain features of the 
lead compound, 
1.Increase activity against the chosen target. 
2.Reduce activity against unrelated targets. 
3.Improve the drug likeness or ADME properties of molecule. 
DOCKING: 
Molecular docking is generally used to detect the protein-ligand orientation and 
interaction. 
The quality of any docking results depends on the starting structure of both the 
protein and the potential ligand. The protein and ligand structure need to be prepared to 
achieve the best docking results. 
It includes the following steps, 
1. Preparation of receptor & ligand files. 
2. Calculation of affinity maps by using a 3D grid around the receptor & 
ligand. 
3. Defining the docking parameters and running the docking simulation. 
ADME ANALYSIS37: 
Optimization of the ADME (Absorption, Distribution, Metabolism, and 
Excretion) properties of the drug molecule is often the most difficult and challenging part 
of the whole drug discovery process. The ADME profile will also have a major impact on 
the likelihood of success of a drug. If there is any failures, as they do not undergo these 
properties satisfactorily this has to be ruled out earlier in drug discovery process. 
 Many invitro studies and insilico tools are available to evaluate the ADME 
properties. 
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PREDICTION OF ADME RELATED PROPERTIES: 
Absorption: 
To investigate this insilico models uses simple parameters like log D [diffusion 
coefficient] and polar surface area are the descriptors for hydrogen bonding capacity and 
logp (partition coefficient) values should fall under the prescribed values as per the rule 
of five, which determines the absorption. 
Bioavailability: 
Size and shape of the molecules, lipophilicity and flexibility determines the 
bioavailability. 
Metabolism: 
Various in silico approaches are exisiting in evaluating the metabolism namely 
QSAR and 3D QSAR. 
 
HETEROCYCLIC CHEMISTRY: 
Heterocyclic structures always are a part in the field of research and 
development in organic chemistry. Millions of heterocyclic structures are found to exist 
having special properties and biological importance. A series of thiadiazole have been 
synthesized using an appropriate synthetic route and characterized by elemental analysis 
and spectral data. 
The various thiadiazole rings are 
1, 2, 4-Thiadizole 
1, 3, 4-Thiadizole 
1, 2, 5-Thiadizole 
1, 2, 3-Thiadizole 
THIADIAZOLE NUCLEUS: 1, 3, 4-THIDIAZOLE: 
Thiadiazole ring system contains five-membered di unsaturated ring structure 
having molecular structure formula C2H2N2S containing two carbon atoms, two 
hydrogen, two nitrogens and one sulphur. The ending azole designates a five membered 
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ring system with two or more heteroatom, one of which is Nitrogen. Thiadiazoles are 
associated with diverse biological activity probably by virtue of –N=C-S- functional. 
1,3,4- Thiadiazole moiety contain a heterocyclic nucleus in which sulfur is present at 
position -1, and two nitrogen atoms at position-3 & 4. 
 Thiadiazole is biologically identical to that of Pyrimidine and Ox diazole and 
given the prevalence of pyrimidine in nature, it is not surprising that thiadiazole show 
significant therapeutic potential. The Sulfur atom of thiadiazole imparts improved 
liposolubility. 
This literature review shows that the thiadiazole nuclei have various biological 
activities such as 
• Anti-tubercular50,51,52,53, 
• Analgesic and Anti-inflammatory44 
• Anticonvulsant46, 
• Antidepressant48, 
• Antioxidant49, 
• Antihypertensive47, 
• Anti-fungal45. 
In view of the importance of the Thiadiazole nucleus. It was decided to design 
nucleus based on the Thiadiazole nucleus. One hundred different molecules with the 
thiadiazole scaffold were drawn and docked. 
Thiadiazole is a versatile moiety that exhibits a wide variety of biological 
activities. Thiadiazole moiety acts as “hydrogen binding domain” with “two-electron 
donor system”. Many drugs containing thiadiazole nucleus are available in the market 
such as Acetazolamide, Methazolamide, Sulfamethazole,etc. 
Thiadiazole derivatives possess interesting biological activity probably 
conferred to them by the strong aromaticity of this ring system, which leads to great in 
vivo stability and generally, a lack of toxicity for higher vertebrates, including humans. 
When diverse functional groups that interact with biological receptors are attached to this 
ring, compounds possessing outstanding properties are obtained. 
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BIOLOGICAL EVALUATION: 
Microplate Alamar Blue Assay (MABA)74: 
Throughput in tuberculosis drug discovery was extremely limited prior to the 
introduction of microplate-based susceptibility assays. The 96-well Microplate Alamar 
Blue Assay (MABA) allows for the quantitative determination of drug susceptibility 
against any strain of replicating Mycobacterium tuberculosis to be completed within a 
week at minimal cost. 
Cytotoxicity75: 
Cell culture can be used to screen for toxicity both by estimation of the basal 
functions of the cell (i.e. those processes common to all types of cells) or by tests on 
specialized cell functions. General toxicity tests, aimed mainly at detection of the 
biological activity of test substances, can be carried out on many cell types (e.g. 
fibroblasts, HeLa and hepatoma cells).  
A number of parameters including vital staining, cytosolic enzyme release, cell 
growth and cloning efficiency are used as end-points to measure toxicity. Organ-specific 
toxic effects are tested using specialized cells by measuring alterations in membrane and 
metabolism integrity and/or in specific cell functions (e.g. glycogen metabolism in 
primary hepatocyte cultures, beating rate in mixed myocardial cells or myocytes, and 
phagocytosis in macrophages).  
Cytotoxicity tests using specialized cells have proved most useful when the in 
vivo toxicity of a chemical is already well established and where in vitro investigations 
using specialized cell cultures have been used to clarify the mechanisms of toxic action 
on the target tissue. These tests have also provided useful insight into the pathogenesis of 
some human diseases. 
Acute Oral Toxicity76: 
Testing for acute toxicity is the most fundamental of toxicological 
investigations and is routinely performed as a regulatory requirement for a number of 
different substance and product types in order to ensure human safety. The results of 
these studies are used to characterize the hazard, to assign the substance to a 
classification category to provide information on the likely medical treatment. 
Aim  
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AIM AND OBJECTIVE 
 
AIM: 
To design novel molecules with potent anti-tubercular activity which are 
capable of inhibiting cell wall synthesis by inhibiting Glutamine synthetase I. The 
designed molecule will be synthesized, characterized and evaluated for biological activity 
and toxicity. 
 
OBJECTIVE: 
The compounds are designed and docked against a specific crucial target, 
Glutamine synthetase I. This enzyme is involved in the cell wall biosynthesis. The 
synthesized compounds are expected to act on the specific enzyme and inhibit cell wall 
synthesis.  
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PLAN OF WORK 
  Design of Glutamine synthetase I inhibitors by docking studies using AutoDock 
Tools 4® software. 
  Insilico Drug likeness prediction using Molinspiration®. 
  Insilico Toxicity Assessment using Osiris Property Explorer®. 
  Laboratory synthesis of those compounds with top Docking Scores. 
  Characterization of the synthesized compounds by, 
  TLC method 
  Melting point. 
  Infrared Spectroscopy.  
  LC-Mass Spectroscopy. 
  H1 Nuclear Magnetic Resonance Spectroscopy. 
 In-vitro anti -tubercular activity of synthesized compounds (Microplate Alamar 
Blue Assay). 
 Acute Oral Toxicity studies  
  In-vitro cytotoxicity studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLAN OF WORK 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai-03  21 
 
 
THE  STUDY WAS CARRIED OUT BASED ON THIS FLOW CHART: 
 
 
IDENTIFICATION OF LEAD COMPOUND 
 
 
 
LEAD OPTIMIZATION 
 
 
 
DOCKING OF THE MOLECULE TO THE TARGET PROTEIN 
 
 
 
TOP G SCORE COMPOUNDS SELECTED 
 
 
 
INSILICO DRUG LIKENESS AND TOXICITY RISK ASSESSMENT 
 
 
 
SYNTHESIS OF DESINGED MOLECULE 
 
 
 
JUSTIFICATION OF PURITY –TLC, MELTING POINT 
 
 
 
CHARACTERIZATION –SPECTROSCOPY(IR, NMR, LC-MS) 
 
 
 
INVITRO ANTI TUBERCULAR ACTIVITY(MABA) 
 
 
ACUTE ORAL TOXICITY STUDY 
 
INVITRO CYTOTOXICITY STUDY 
Flow chart 1: Plan of work 
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LIST OF COMPOUNDS TO BE SYNTHESIZED: 
 
Table 1. List of compounds to be synthesized 
SAMPLE 
CODE 
STRUCTURE IUPAC NAME 
 
 
 
 
 
BOB 
        
 
 
 
   5 - ({(E) - [ 4- 
(benzyloxy)phenyl] 
methylidene} amino)- 
   1,3,4-thiadiazole-2-thiol 
 
 
 
 
 
 
CIN 
 
 
 
      
 
 
 
   5 - {[(1E, 2E) -3-phenylprop-
2- en-1-ylidene] amino}- 
   1,3,4-thiadiazole-2-thiol 
 
 
 
 
 
 
NIB 
 
 
 
       
 
 
   5 - {[(E) - (3-nitrophenyl)    
methylidene] amino}-  
   1,3,4-thiadiazole-2-thiol 
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SAMPLE 
CODE 
STRUCTURE IUPAC NAME 
 
 
 
 
 
OHB 
        
 
     2 - {(E) - [(5-sulfanyl- 
   1,3,4-thiadiazol-2-yl) 
   imino] methyl}phenol 
 
        
 
 
 
 
 
   4 - {(E) - [(5-sulfanyl- 
1,3,4- thiadiazol-2-yl) 
imino]methyl}phenol 
 
 
 
 
 
 
 
PHB 
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LITERATURE REVIEW 
 
 
The purpose of Literature Review is to: 
 Establish a theoretical frame work for a topic/ subject area 
 Define Key terms and terminology 
 Identify studies, Models, Case studies etc supporting a topic 
 Define/establish an area of Study 
 
Reviews related to the target- Glutamine synthetase I: 
1. Gunter Harth and Marcus A. Horwitz demonstrated that inhibitors of extracellular 
Glutamine synthetase block the growth of M. tuberculosis and other pathogenic 
mycobacteria. Remarkably, the inhibitors were selective for pathogenic mycobacteria, 
which export Glutamine synthetase and contain the poly-l-glutamate/ glutamine cell wall 
structure. Extracellular Glutamine synthetase is clearly a prime target of the irreversible 
Glutamine synthetase inhibitor l-methionine- S-sulfoximine. The inhibitor reduced 
Glutamine synthetase activity in the extracellular milieu of M. tuberculosis cultures by 
80% but had little effect on cell-associated Glutamine synthetase38. 
2.Marcus A. Horwitz et al., assessed the role of Glutamine synthetase (GS), in the 
pathogenicity of Mycobacterium tuberculosis; glnA1 was constructed via allelic 
exchange. The mutant had no detectable Glutamine synthetase protein or Glutamine 
synthetase activity and was auxotrophic for L-glutamine. In addition, the mutant was 
attenuated for intracellular growth in human THP-1 macrophages. Based on growth rates 
of the mutant in the presence of various concentrations of L-glutamine the importance of 
the enzyme was known. These studies demonstrate that glnA1 is essential for 
M.tuberculosis virulence39. 
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3.Lukasz Berlicki studied about the Glutamine synthetase enzyme which catalyses the 
formation of glutamine from glutamine and ammonium ion. It is one of the most 
important enzymes in nitrogen metabolism. The first part of the review presents the long-
dating research on inhibitors of Glutamine synthetase. The second part of the paper is 
dedicated to potential medical applications of Glutamine synthetase inhibitors, which is 
proved as effective anti-tuberculosis agent with high selectivity towards the pathogen40. 
4.O Lagerlund synthesized some potential anti-tubercular agents which targeted 
Glutamine synthetase (GS), which is one of the latest targets of M.tuberculosis which 
catalyses the formation of glutamine from glutamic acid. In this work, novel Glutamine 
synthetase inhibitors and new Pd (O) - catalyzed methods have been developed41. 
5.Wojciech W. Krajewski et al., summarized that Glutamine synthetase catalyzes the 
ligation of glutamate and ammonia to form glutamine, with the hydrolysis of ATP. The 
enzyme is a central component of bacterial nitrogen metabolism and is a potential drug 
target. This study provides the first reported structure for a tauto form of the tuberculosis 
enzyme. 
The phospho compound, generated in situ by an active enzyme, mimics the 
phosphorylated tetrahedral adduct at the transition state. Some differences in ligand 
interactions of the protein with phosphorylated compound and nucleotide were observed 
compared with the earlier structures; a third metal ion also was found42. 
 
The review on following works provided ideas about the Thiadiazole Nucleus and its 
Biological Activity. 
Antimicrobial activity:- 
6.Kumar, et al., (2011), synthesized the heterocyclic azodyes derived from thiadiazole 
and evaluated them for antimicrobial activity. In this study 5-ethyl-1, 3, 4- thiadiazole-2-
amine was synthesized by a single step reaction. A series of heterocyclic azodyes were 
synthesized by coupling 8-hydroxyquinoline, 2, 6-diaminopyridine, N, N- dimethyl 
aniline, 2-napthol and resorcinol with diazotized 5-ethyl-1, 3, 4-thiadiazol-2-amine in 
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nitrosyl sulphuric acid. The synthesized compounds were also screened for biological 
activity and showed maximum activity43. 
N
N
N
OH
N
S
N CH3 
Anti inflammatory and analgesic activity:- 
7.Sainy et al., (2009), synthesized a series of 2- amino-5-sulfanyl-1, 3, 4-thiadiazole 
derivatives and several 2-amino-5-sulfanyl-1, 3, 4- thiadiazoles and concluded that the 
compounds were associated with lesser degree of anti- inflammatory activity when 
compared to indomethacin. Only compound 4-[5-(4- Fluorophenylsulfanyl) -[1,3,4] 
thiadiazol-2-ylamino] benzene sulfonamide showed 65.90% inhibition of paw edema 
after 3 h at 56 mg/kg (body weight) dose and 66.40% protection in acetic acid induced 
inflammation in mice44. 
 
NH
N
S
N
S
OH
S
O
OH
NH
N
S
N
S
Br
S
O
OH
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Antifungal Activity:- 
8.Liu et al., (2011), reported the antibacterial and antifungal activity of 1,3,4-thiadiazoles 
bearing imidazo [2,1-b] thiazole moiety against S. aureus ATCC 29213, P. aeruginosa 
ATCC 27853, E. coli ATCC 25922, and T. tonsurans NCPF245 with MIC of 64, 32, and 
8 μg/ml, respectively. Applying QSAR study, it has been observed that positions-2 or 
position-3 of benzene attached with thiadiazole ring where as electron- donating and 
bulky group would be favorable for higher antifungal activity45. 
N
N
S
NH
O
 
 
Anticonvulsant activity:- 
9.Sharma et al., (2011), synthesized a new series of 2-amino-5- sulfanyl-1, 3, 4-
thiadiazole derivatives. All compounds were screened for central nervous system activity. 
They exhibit significant antidepressant, anxiolytic and anticonvulsant activity when 
compared with the standard drugs46. 
N
N
S
NH
S
R
R
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Antihypertensive activity:- 
10.Turner et al., (1998), synthesized a series of antihypertensive thiadiazole derivatives 
and evaluated them for antihypertensive activity and indicated higher activity when 
compared with the standard compounds47. 
R
N N
S
NH
NH2
 
 
Antidepressant and Anxiolytic Activity:- 
11.Francesca Clerici et al., (2000), A series of 2-amino-5-sulfanyl-1,3,4-thiadiazole 
derivatives bearing different substituents were synthesized and screened 
pharmacologically in order to evaluate their central nervous system activity. The purpose 
of this study was to evaluate the effects of the title compounds on CNS activity by 
varying the substituents in the thiadiazole moiety. It was found that some of these 
compounds possess marked antidepressant and anxiolytic properties comparable in 
efficiency to the reference drugs Imipramine and Diazepam48. 
S
N N
SNH2
O
CH3  
Anti-Oxidant activity and Mucomembranous protector:- 
12.Bijo Mathew and Jerad Suresh et al., (2012),  A series of some novel imines of 2-
amino, 5-thio 1,3,4-thiadiazole connected to benzimidazole chalcones were prepared. 
Predicted activity spectra of all the final derivatives were determined in the category of 
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mucomembranous protector nature with a pka value more than 0.7. All the newly 
synthesized compounds were screened for their antiulcer activity in the pylorus-ligated 
rats49.  
N
N
S
SH
N
R
N
NH
 
Anti tubercular activity:- 
13.Foroumadi et al., (2002), Synthesized 2-(5-nitro-2-furyl) and 2- (1-methyl- 5-nitro-
lH- imidazol-2-yl)-1, 3, 4-thiadiazole derivatives and evaluated in vitro anti tuberculosis 
activity. In this study two series of 2-(5-nitro-2-furyl) and 2-(1-methyl-5- nitro-lH-
imidazol-2-yl)-5-propyl, ally and propargyl) thio-l,3,4-thiadiazoles derivatives and 2-(5-
nitro-2-furyl)- and 2-(1-methyl-5-nitro-lH-imidazol- 2-yl)-5-(nitro benzyl)thio-l,3,4- 
thiadiazole derivatives were synthesized and evaluated against Mycobacterium 
tuberculosis and found to exhibit good activity50. 
N
N
S
Ar
-
S
R
 
 
14.Noolvi M.N et al., (2013), synthesized a series of imidazo [2, 1-b] 1, 3, 4- thiadiazole 
derivatives. The synthesized compounds were evaluated for their invitro anti tubercular 
activity against M. tuberculosis H37Rv strain by using Alamar Blue susceptibility test. 
Among the tested compounds, 2-(1-methylimidazol-2- yl)-6-(4-nitrophenyl) imidazo [2, 
1-b] 1, 3, 4-thiadiazole have shown the highest inhibitory activity with MIC of 
3.125µg/ml as compared to other compound51. 
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N
N
S
Ar
-
S
R
 
15.Gadad A.K et al., (2004), Evaluated 6-aryl-2-triflouromethylimidazo [2, 1-b] 1, 3, 4- 
thiadiazole derivatives against M. tuberculosis ie. H37Rv strain by radiometric BACTEC 
and broth dilution method. It was found that 4-flouro phenyl derivative causes maximum 
inhibition at 6.25µg/ml concentration. All the synthesized compounds were reported to be 
less active than standard drug Isoniazid52. 
N N
S N
OH
 
16.Shiradhkar M et al., (2005), synthesized a series of S-triazolo [3, 4-b] 1, 3, 4-
thiadiazoles and screened for their antitubercular activity against M. tuberculosis H37Rv. 
The final data of the MIC was compared with the standard drug Rifampicin at 0.03µg/ml 
concentration which showed more than 95% inhibition. Among the derivatives, nitro 
phenyl derivatives were shown to possess maximum activity against M. tuberculosis53. 
R
N
N S
N
R  
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17.Palkar M.B et al., (2012), synthetized a series of anti-tubercular activity of some 2-
substituted-5, 6-diaryl substituted imidazo [2, 1-b] 1, 3, 4-thiadiazoles against M. 
tuberculosis H37Rv strain by Micro plate Alamar Blue Assay (MABA) method. Among 
synthesized compounds, the below represented compound (MIC =1.25 lg/ml) exhibited 
excellent anti-tubercular activity with respect to other synthesized compounds and 
reference drugs54. 
N
N
N
S
O
O
CH3
CH3
S
O
O
NH2
 
 
The review on following works provided ideas for synthesis of the desired chemical 
entities:- 
18.Tang, Zilong et al., (2015), synthesized 2-[1, 3, 4-thiadiazolyl amino methyl] phenols 
by one pot reaction of 2-amino -5-Alkyl [aryl] - 1, 3, 4-thiadiazole and salicylaldehyde. 
The title compounds had moderate fungicidal activity55. 
 
N
N
S
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19.Sandeep Miglani, et al., (2012), reported the rapid synthesis of Schiff-bases without 
solvent under microwave irradiation and their antimicrobial activity It was observed that 
meta-substituted compounds exhibited good activity against almost all the organisms 
used in the study56. 
+
O N
NH2
R2 R1
R2
R1
 
 
The following literature provide supporting data for the drug design study:- 
20.Wermuth C G., (2006) reviewed the similarity in drugs with the importance and 
reflections on analogue design. He also clarified the terminology of analogue design by 
establishing a clear distinction among three kinds of analogues57. 
21.Kore P P et al., (2012) reviewed a brief history of CADD, DNA as target, receptor 
theory, structure optimization, structure-based drug design, virtual high-throughput 
screening (vHTS) and graph machines58. 
22.Frederick W G et al., (2015) outlined the general principles that should be applied to 
ensure the building block collection’s impact on drug discovery projects59. 
 
The review on following works revealed the basis of Microplate Alamar Blue Assay 
for evaluating the anti-mycobacterium action:- 
23.David A. J. Moore., et al., (2008), reported inter and intra assay reproducibility of 
Microplate Alamar Blue Assay results for Isoniazid, Rifampicin, Ethambutol, 
Streptomycin, Ciprofloxin, Capreomycin, drug susceptibility testing Mycobacterium 
tuberculosis60. 
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24.Vanitha J D., et al., (2007), reported the evaluation of Microplate Alamar Blue Assay 
for drug susceptibility testing of Mycobacterium avium complex isolates61. 
25.Franzblau S G., et al., (1998), reported the, Rapid lower technology MIC 
determination with clinical Mycobacterium tuberculosis isolates by using the Micro plate 
Alamar blue assay. Journal of Clinical Microbiology62. 
26.Jose d Jesus Alba-Romero.,et al., (2014) applied the Microplate Alamar Blue Assay 
to determine the susceptibility to anti-tuberculosis pharmaceuticals. The results showed 
that the MABA test is fast and easy to apply. It is very reliable method to determining the 
drug susceptibility to pharmaceuticals63. 
 
The review on following works revealed the basis of Acute Oral Toxicity on Mice:- 
27.Erik Walum.,(1998) gives a short review of methods for acute toxicity testing with 
the emphasis on the median lethal dose (LD50) test and alternative procedures that fulfill 
the requirement of reducing, refining, or replacing the use of animals in toxicity testing 
(the 3R principle). Furthermore, this review mirrors the current discussion on the 
usefulness of different procedures for acute toxicity testing and surveys the conclusions 
of various panels, commissions, and groups64. 
28. Gerald L. Kennedy, (1986) studied the reduction of the numbers of experimental 
animals used in test programs while minimizing the extent of information. In working 
with newly synthesized chemicals or adapting chemicals for new end-uses, the definition 
of the biologic spectra of effects produced includes estimation of the amount necessary to 
produce biologic signs of response up to and including death. Traditionally, the LD,, was 
used to obtain this information using laboratory species such as the rat, mouse, guinea pig 
and hamster65. 
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4. MATERIALS AND METHODS 
 
DRUG DESIGN66:- 
The molecular designing of drugs for specific purposes (such as DNA-binding, 
enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties 
such as activity of functional groups, molecular geometry, and electronic structure, and 
also on information cataloged on analogous molecules. 
Drug design is generally computer-assisted molecular modeling and does not 
include pharmacokinetics, dosage analysis, or drug administration analysis. 
DOCKING STUDY:- 
Molecular docking is generally used to detect the protein-ligand orientation and 
interaction. AutoDock Tools package was utilized to create the docking input files. The 
grid region was surrounded by the active site for binding. Docking of ligands is carried 
out by Autodock 4® software. 
Docking allows the medicinal chemist to virtually screen a set of compounds 
and predict the strongest binding capacity based on various scoring function. It explores 
ways in which two molecules such as ligand and receptor (protein) fit together and docks 
to each other well. The molecule binding to a receptor inhibits its function and thus acts 
as drug. 
Working with AutoDock 4® includes 3 steps: 
1. Preparation of receptor & ligand files. 
2. Calculation of affinity maps by using a 3D grid around the receptor & ligand. 
3. Defining the docking parameters and running the docking simulation. 
The preparation step starts with pdb files of receptor (protein.pdb) and ligand 
(ligand.pdb), to which are added hydrogens and then saved as protein.pdb & ligand.pdb. 
The calculation of affinity maps in the "Grid" section requires the above pdb files to be 
assigned charges & atom types, and also that the nonpolar hydrogens are merged. This is 
done automatically by AutoDock tools, and the resulting files need to be saved as 
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protein.pdbqt & ligand.pdbqt, which is the only format AutoGrid & AutoDock can work 
with. Calculation of affinity maps is done by AutoGrid, and then docking can be done by 
AutoDock. The newest docking algorithm is LGA (Lamarckian Genetic Algorithm). 
For running AutoDock tools, the following steps are required. 
1. Install MGL (Molecular Graphics Laboratory) tools. 
2. Download autogrid4.exe, autodock4.exe and AD4.1_bound.dat files. 
3. Install Molegro Molecular Viewer®. 
4. Install ChemBioDraw® including 3D Pro. 
For docking the Enzyme and Ligand is needed. The enzyme which is 
downloaded from (Research Collaboratory for Structural Bioinformatics) RCSB 
Protein Data Bank as PDB format. The Protein Data Bank (PDB) is a crystallographic 
database for the three-dimensional structural data of large biological molecules, such 
as proteins and nucleic acids. The data, typically obtained by  X-ray crystallography,   
NMR spectroscopy,   or, increasingly,  Cryo-electron microscopy, and submitted by 
 biologists  and biochemists from around the world, are freely accessible on the Internet 
via the websites of its member organisations (PDBe, PDBj, and RCSB). 
Criteria to select the best protein structure from PDB67:- 
1. Resolution must be minimum possible (This will ensure the better quality of 
protein structure). 
2. Domain completeness. The PDB structure is examined and confirmed that the 
under study domain’s full structure available. Partial domain will lead to false 
interpretations. 
3. Variant /Mutations. We need to look for whether the structure is a wild type 
or a mutant/variant. In case of a mutant structure requirement we may have to introduce 
required mutations manually and model them. 
4. Side Chain Completeness (is of secondary importance). Structures 
determined through old techniques might have (Not always) missing side chains due to 
flaw in tech or manual error. Right 3D confirmation of side chains is critical in small 
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ligand binding thus ensuring their completeness is important. As a possible solution we 
may look for latest structure availability of the same. 
5. Ligand /Crystalline Water / Co factor presence. To get out the right docking 
result removal (As per case study) of these elements form PDB file is important. 
 According to the above criteria the Glutamine synthetase I enzyme 3zxr as pdb 
format was downloaded which has a X-ray resolution of 2.15 Ao and the structure was 
detected by X-ray Diffraction method.  
After having finished installation of above tools, we can run AutoDock Tool. 
1. Create a work folder for the job and tag it based any name. 
2. Running ADT in start menu in windows: > after running we should set its 
directory by the following steps: 
Open ADT> File> Preferences>set> Startup Directory (in this section you should 
put on the workfolder path and set it). 
3. Prepare ligand and protein in ".pdb" format. Notice, we must have labeled 
them by "Ligand" and "Protein" keywords. Protein can be preprocessed by Molegro 
Molecular Viewer® & Ligand can be initially prepared using in ChemBioDraw® and can 
be saved as pdb. 
 
Preparation of Protein: 
1. File > Read Molecule> Select Protein File (“.pdb” file). 
2. Edit > Hydrogens >Add>Polar Only >OK. 
3. Edit > Hydrogens > Merge Non-Polar > Continue ( if warning appears in this 
step please click on "continue"). 
4. Edit > Charges > Compute Gasteiger > OK. 
5. Edit > Misc > Repair Missing Atoms > Ok/Select all > Dismiss. 
6. File > Save > Write PDB> >Sort Nodes (Check) > OK > (Overwrite) YES. 
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Preparation of Ligand: 
1. Ligand > Input > Open> Select Ligand File (“.pdb” file) > OK. 
2. Edit> Charges> Add Kollman charges. 
3. Ligand > Output > Save as PDBQT. 
Executing AutoGrid4: (Preparing gpf file) 
1. Grid > Macromolecule > Choose > Click (Protein) > Select Molecule > OK > 
Save as PDBQT. 
2. Grid> Set Map types > Choose Ligand > Click ‘Ligand’ > Select ‘Ligand’. 
3. Grid > GridBox> Set the BOX to comprise the active aminoacid of the 
macromolecule > Center> Pick an atom> Center> Center on Macromolecule > File > 
Close Saving Current. 
4. Grid > Output > Save GPF> grid.gpf> save. 
Executing AutoDock4: (Preparing dpf file) 
1. Docking > Macromolecule > Set Rigid filename> Select ‘Protein.pdbqt’ > 
Open. 
2. Docking > Ligand > Choose> Click ‘Ligand’ > Select ‘Ligand’ > Accept. 
3. Docking > Search Parameters > Genetic Algorithm> Accept. 
4. Docking > Output > Lamarckian GA> Save file as ‘dock.dpf’. 
The autogrid4.exe, autodock4.exe and AD4.1_bound.dat files are copied into 
the destination folder (working folder) and checked whether pdbqt file, grid.gpf and 
dock.dpf files are there. 
1. Open cmd (command prompt). Windows +R and type cmd enter. 
2. In command prompt, the destination folder is directed by cd commands. 
3. Run the following commands. 
4. Autogrid4.exe -p grid.gpf -l grid.glg (wait for the response). 
5. Autodock4.exe -p dock.dpf -l dock.dlg wait for the response). 
6. The dock.dlg file is the docking result. 
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Analysing the Results: (Screening) 
1. Analyze > Docking > Open> Select ‘dock.dlg’ > Open >Assign Ligand New 
Name > OK. 
2. Analyze> Macromolecule > Choose > Click‘Protein’>Select Macromolecule. 
3. Analyze > Conformations > Play, Ranked By Energy or Play > Click on the 
‘&’ Button. 
4. Set Play Options > Check ‘Build H-Bonds’ > View the hydrogen bonds 
formed > Check ‘Show Info’> View the Interaction Energy > Build Current Write 
Complex > Save as ‘Result.pdb’. 
5. For better ligand interactions open the result.pdb in Molegro Molecular 
Viewer® and view it and save the ligand interaction as image. 
During the docking process, a maximum of 10 conformers are considered for 
each compound. This method was applied for each designed compound and after 
completion the conformer with lowest binding energy was chosen.  
The conformational similarity by visualizing the binding site and its energy 
(Kcal/mol), and the docked amino acid residues forming hydrogen bonds and other 
parameters like intermolecular energy (Kcal/mol) and inhibition constant (μM) were 
analyzed by AutoDock tool. Ten best poses were generated for each ligand and scored 
using AutoDock 4® scoring functions. Based on the docked energy all the ligands were 
ranked. The ligand interacting residues with the target protein were analyzed using 
Molegro molecular Viewer®. 
LIPINSKIS RULE68,69:- 
Lipinski’s rule of five is a rule of thumb to evaluate drug likeness, or to 
determine if a chemical compound with a certain pharmacological or biological activity 
has the properties that would make it a likely orally active drug in humans. The rule was 
formulated by Christopher A. Lipinski in 1997, based on the observation that most 
medication drugs are relatively small and lipophilic molecules. 
The rule describes molecular properties important for a drug’s pharmacokinetics 
in the human body, including their absorption, distribution, metabolism and excretion 
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(ADME). However, the rule does not predict if a compound is pharmacologically active. 
The rule is important for the drug development where a pharmacologically 
active lead structure is optimized step-wise for increased activity and selectivity, as well 
as drug-like properties as described by Lipinski’s rule. The modification of the molecular 
structure often leads to drugs with higher molecular weight, more rings, more rotatable 
bonds, and a higher lipophilicity. 
Lipinski’s rule says that, an orally active drug has no more than one violation of 
the following criteria: 
1. Not more than 5 Hydrogen bond donors (Nitrogen or Oxygen atoms with one or 
more Hydrogen atoms) 
2. Not more than 15 rotatable bonds. 
3. Not more than 10 Hydrogen bond acceptors (Nitrogen or Oxygen atoms) 
4. Molecular weight under 500 Daltons 
5. Partition coefficient of log P less than 5. 
Variants 
In an attempt to improve the predictions of druglikeness, the rules have spawned 
many extensions,  
1. Partition coefficient log P in −0.4 to +5.6 range 
2. Molar refractivity from 40 to 130 
3. Molecular weight from 180 to 500 
4. Number of atoms from 20 to 70 (includes H-bond donors [e.g. OHs and NHs] and 
H-bond acceptors [e.g. Ns and Os]) 
Also the 500 molecular weight cutoff has been questioned. Polar surface area 
and the number of rotatable bonds has been found to better discriminate between 
compounds that are orally active and those that are not for a large data set of compounds 
in the rat. 
 In particular, compounds which meet only the two criteria of: 
1. 10 or fewer rotatable bonds and 
2. Polar surface area no greater than 140 A2 
are predicted to have good oral bioavailability. 
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INSILICO PREDICTION37: 
The synthesized molecules are predicted of their toxicity risk and some 
significant physicochemical properties were performed using OSIRIS-Property-Explorer. 
It is a free tool to predict physico-chemical and toxicological molecular properties, which 
need to be optimized when designing pharmaceutically active compounds. For predicting 
properties of a chemical compound just draw its structure and Property Explorer will start 
calculating properties as soon as a chemical structure is valid. Charges should be 
balanced and atom valances not exceeded. Nitro-groups, for instance, should be drawn 
with a positive charge on nitrogen and a negative on one of the oxygens with a single 
bond connecting these two atoms. For an explanation of the significance of a specific 
property and the calculation algorithm applied see the corresponding page below: 
1. Molecular Weight  5. Drug-Likeness 
2. Calculated LogP  6. Toxicity Assessment 
3. Aqueous Solubility  7. Overall Drug-Score 
4. TPSA 
It also shows the toxicological predictions such as Mutagenic, Tumorigenic, 
Irritant and Reproductive effect. 
Property Explorer Applet predicts physico-chemical properties and detects 
potential toxicity risks for any drawn chemical structure in real time. Prediction results 
are valuated and color coded. Unfavorable properties or those with a high risk of side 
effects like mutagenicity or poor intestinal absorption are shown in red. Green color 
instead indicates drug-conform behaviour. 
MOLINSPIRATION®: 
Molinspiration® is an online tools to calculate the molecular properties 
including PSA, Rule of 5 parameters and molecular drug-likeness by drawing the  
structure of the docked molecule by the use of online provided tools.  
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SYNTHETIC METHODOLOGY70,71,: 
The designed and docked compounds can be synthesized by the following 
scheme (Schiff base synthesis) which is presented below. 
In a round bottom flask, equimolar mixture of an aldehyde or ketone and amine  
in ethanol is taken. The resulting mixture is refluxed for about 4-5 hours at 60 to 80oC 
temperature. The progress of the reaction is monitored by TLC. The mixture is poured on 
to crushed ice. The precipitate obtained is filtered by whatmann filterpaper. The pure 
product is obtained upon recrystallization of the residue from ethanol, when necessary. 
All the products are known imines and their structures were secured on the basis of their 
analytical and/or spectral data, compared with literature data. 
SYNTHETIC SCHEME72: 
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REACTION MECHANISM73: 
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MATERIALS 
Substituted Aromatic Primary Amine :  
5-AMINO-1,3,4-THIADIAZOLE-2-THIOL  
Substituted Aromatic Aldehydes :  
1. 4-(BENZYLOXY) BENZALDEHYDE 
2. CINNAMALDEHYDE 
3. 3-NITRO BENZALDEHYDE 
4. 2-HYDROXY BENZALDEHYDE 
5. 4-HYDROXY BENZALDEHYDE 
 
 
REACTANT PROFILE: 
5-AMINO-1,3,4-THIADIAZOLE-2-THIOL: 
N N
S
H2N SH
 
Synonym  : 2-Amino-1,3,4-Thiadiazole-5-Thiol 
Molecular Formula : C2H3N3S2 
Molecular weight : 133.195  
Description  : White or Pale yellow to cream powder 
Melting point  : 235oC 
Solubility  : Slightly in Methanol, Sparingly in Chloroform 
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4-(BENZYLOXY) BENZALDEHYDE: 
 
O
O
 
 
Synonym  : 4-(PhenylMethoxxy) Benzaldehyde 
Molecular Formula : C14H12O2 
Molecular weight : 212.244  
Description  : Creamish to Yellow crystalline powder 
Melting point  : 71-74oC 
Solubility  : Slightly in Chloroform, Sparingly in Ethyl acetate 
 
 
CINNAMALDEHYDE: 
 
O
 
 
Synonym  : 3-Phenylpropenal 
Molecular Formula : C9H8O 
Molecular weight : 132.159  
Description  : Pale Yellow viscous liquid 
Boiling point  : 250-252oC 
Solubility  : Soluble in Ether and Chloroform 
Density  : 1.05 g/ml at 25oC 
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3-NITRO BENZALDEHYDE: 
 
O2N
O
 
 
Synonym  : m-Nitro Benzaldehyde 
Molecular Formula : C7H5NO3 
Molecular weight : 151.119 
Description  : Yellowish to Brownish crystalline powder to granulate 
Melting point  : 58.5oC 
Solubility  : Slightly in water 
 
2-HYDROXY BENZALDEHYDE: 
 
O
OH
 
 
Synonym  : Salicylaldehyde, o-Hydroxy Benzaldehyde 
Molecular Formula : C7H6O2 
Molecular weight : 122.121 
Description  : Clear Yellow liquid 
Boiling point  : 197oC 
Solubility  : Slightly in water 
Density  : 1.146 g/ml at 25oC 
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4-HYDROXY BENZALDEHYDE: 
 
O
HO  
 
Synonym  : p-Hydroxy Benzaldehyde 
Molecular Formula : C7H6O2 
Molecular weight : 122.121 
Description  : Light Yellow to Light Brown crystalline powder 
Melting point  : 112-116oC 
Solubility  : soluble in water and Ethanol 
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List of Compounds to be Synthesized: 
The 5-Amino-1,3,4-Thiadiazole-2-Thiol an amine can be reacted with 
following aldehydes such as  4-(Benzyloxy) Benzaldehyde, Cinnamaldehyde, 3-Nitro 
Benzaldehyde, 2-Hydroxy Benzaldehyde, 4-Hydroxy Benzaldehyde separately and to 
form corresponding Schiff bases. 
Table 2. List of compounds to be synthesized 
Sample code Structure of the Molecule IUPAC Name 
 
 
 
 
BOB 
 
 
 
 
 
5 - ({(E) - [ 4- 
(benzyloxy)phenyl] 
methylidene} amino)- 
   1,3,4-thiadiazole-2-
thiol 
 
 
 
 
 
CIN 
   
 
 
 
  5 - {[(1E, 2E) -3-
phenylprop-2- en-1-
ylidene] amino}- 
   1,3,4-thiadiazole-2-
thiol 
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Sample code Structure of the Molecule IUPAC Name 
 
 
 
 
NIB 
 
 
 
 
 
   5 - {[(E) - (3-
nitrophenyl)    
methylidene] amino}-  
   1,3,4-thiadiazole-2-
thiol 
 
 
 
 
 
OHB 
    
 
 
 
 
   2 - {(E) - [(5-sulfanyl- 
   1,3,4-thiadiazol-2-yl) 
   imino] methyl}phenol 
 
 
 
 
 
PHB 
 
  
 
 
 
 
  4 - {(E) - [(5-sulfanyl- 
1,3,4- thiadiazol-2-yl) 
imino]methyl}phenol 
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CHARACTERIZATION METHODS: 
  TLC method 
  Melting point. 
  Infrared Spectroscopy. 
   LC-Mass Spectroscopy 
  H1 Nuclear Magnetic Resonance Spectroscopy. 
Thin Layer Chromatography:( Ascending Technique) 
Precoated TLC plates with Silica Gel GF 250 are used. Samples of Reactants 
and Products are prepared with suitable solvents. The plates are cutted to optimum size 
for spotting the samples. Then the TLC development chamber was saturated with suitable 
mobile phase (n-Hexane: Methanol: Ethyl acetate) of different ratios for 15 to 20 min. 
After saturation the samples are spotted carefully on the TLC plates. Then the plates are 
kept inside the chamber for elution of the sample. After elution the plates are removed 
from the chamber and dried. Then the plates are viewed under UV chamber by Physical 
method or Chemical method by Iodine chamber. If the single spot was observed 
indicating the completion of the reaction. The Rf was calculated by the following 
formula, 
Rf   = Distance travelled by the solute / Distance travelled by the solvent 
The different mobile phase was used to confirm the completion of the reaction. 
Melting Point: 
The physical properties of a compound, such as melting point and boiling point 
can provide useful information which can help in the identification of a sample or to 
establish its purity. The temperature at which a solid melts and becomes a liquid is the 
melting point. Since this requires that the intermolecular forces that hold the solid 
together have to be overcome, the temperature at which melting occurs will depend on 
the structure of the molecule involved - an example of the relationship between structure 
and properties. Hence, different compounds tend to have different melting points.  
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A pure, nonionic, crystalline organic compound usually has a sharp and 
characteristic melting point (usually 0.5-1.0oC range). A mixture of very small amounts 
of miscible impurities will produce a depression of the melting point and an increase in 
the melting point range. Consequently, the melting point of a compound is a criterion for 
purity as well as for identification. 
 The melting point of an organic solid can be determined by introducing a tiny 
amount into a small capillary tube, attaching this to the stem of a thermometer centred in 
a heating bath, heating the bath slowly, and observing the temperatures at which melting 
begins and is complete. 
Infra-Red Spectroscopy: 
IR (region 2.5-15 μ) is a powerful tool for identifying pure organic and inorganic 
compounds because. With the exception of a few homo nuclear molecules such as O2, N2, 
C14 all the molecular species absorb infrared radiation. With the exception of chiral 
molecules in the crystalline state, each molecular species has a unique infrared absorption 
spectrum. 
Mass Spectroscopy: 
Mass spectroscopy is an analytical techniques used to establish the molecular 
structure and the molecular weight of the analyte under investigation. In this technique, 
the compound under investigation is bombarded with a beam of electrons producing ionic 
fragments of the original species. The relative abundance of the fragment ion formed 
depends on the stability of the ion and of the lost radical. The resulting charged particles 
are then separated according to their masses. Mass spectrum is a record of information 
regarding various masses produced and their relative abundances. 
Liquid Chromatography–Mass Spectrometry (LC-MS) is an analytical 
chemistry technique that combines the physical separation capabilities of liquid 
chromatography (or HPLC) with the mass analysis capabilities of mass spectrometry 
(MS). Coupled chromatography - MS systems are popular in chemical analysis because 
the individual capabilities of each technique are enhanced synergistically. While liquid 
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chromatography separates mixtures with multiple components, mass spectrometry 
provides structural identity of the individual components with high molecular specificity 
and detection sensitivity. This tandem technique can be used to analyze biochemical, 
organic, and inorganic compounds commonly found in complex samples of 
environmental and biological origin. Therefore, LC-MS may be applied in a wide range 
of sectors including biotechnology, environment monitoring, food processing, and 
pharmaceutical, agrochemical, and cosmetic industries. 
H1 Nuclear Magnetic Resonance Spectroscopy: 
Nuclear magnetic resonance involves the interaction between oscillating 
magnetic field of electromagnetic radiation and the magnetic energy of the hydrogen 
nucleus or some other type of nuclei when these are placed in an external static magnetic 
field. 
NMR enables us to study the number of equivalent protons and their electronic 
environment. It reveals the different chemical environment in which the proton is present 
and helps us to ascertain the structure of molecule. 
The number of signals in an NMR spectrum denotes the number of the set of 
equivalent protons in a molecule. The position of the signals in the spectrum helps us to 
know the nature of protons such as aromatic, aliphatic, acetylenic, vinyl, adjacent to some 
electron attracting or electron releasing group etc. the splitting of the signal is due to the 
different environment of the absorbing proton with respect to the adjacent protons and 
not with respect to electrons. 
 
BIOLOGICAL EVALUATION: 
IN-VITRO ANTI – TUBERCULAR ACTIVITY BY MICROPLATE ALAMAR 
BLUE ASSAY. 
 
1) The anti mycobacterial activity of compounds were assessed against M. tuberculosis 
using microplate Alamar Blue assay (MABA).  
2) This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with propotional and BACTEC radiometric method.  
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3) Briefly, 200μl of sterile deionzed water was added to all outer perimeter wells of 
sterile 96 wells plate to minimized evaporation of medium in the test wells during 
incubation. 
4) The 96 wells plate received 100 μl of the Middlebrook 7H9 broth and serial dilution of 
compounds were made directly on plate.  
5) The final drug concentrations tested were 100 to 0.2 μg/ml.  
6) Plates were covered and sealed with parafilm and incubated at 37ºC for five days.  
7) After this time, 25μl of freshly prepared 1:1 mixture of Almar Blue reagent and 10% 
tween 80 was added to the plate and incubated for 24 hrs.  
8) A blue color in the well was interpreted as no bacterial growth, and pink color was 
scored as growth.  
9) The MIC was defined as lowest drug concentration which prevented the color change 
from blue to pink. 
Standard Strain used: Mycobacteria tuberculosis (Vaccine strain, H37 RV strain): ATCC 
No- 27294.  
Standard values for the Anti-Tb test which was performed.  
Pyrazinamide- 3.125μg/ml  
Ciprofloxacin-3.125μg/ml  
Streptomycin- 6.25μg/ml 
ACUTE ORAL TOXICITY STUDY: 
Acute oral toxicity study (Limit Test) was designed as per the OECD guidelines (423). 
Principles and purpose 
The main purpose of acute toxicity is to evaluate the degree of toxicity in a 
quantitative and qualitative manner. 
Experimental Animals 
Six healthy adult Albino mice were weighing between 20-25g were selected for 
the study. For all the six animals food, but not water was withheld overnight prior to 
dosing. 
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Selection of dose levels and administration of dose: 
Being synthetic molecules, the mortality was unlikely at the highest starting 
dose level (2000mg/kg/b.w). Hence a limit test one dose levels of 2000mg/kg/b.w was 
conducted in all animals as per the OECD guidelines (423). 
Procedure: 
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. However, the duration of observation should not be fixed rigidly. It should be 
determined by the toxic reactions, time of onset and length of recovery period, and may 
thus be extended when considered necessary. The times at which signs of toxicity appear 
and disappear are important, especially if there is a tendency for toxic signs to be 
delayed. All observations are systematically recorded with individual records being 
maintained for each animal. 
CYTOTOXICITY EVALUATION77: 
Material: 
Cell line: Vero (African green monkey kidney cells), DMEM, Fetal Bovine 
Serum (FBS), antibiotic–antimicotic solution and SRB reagent Tissue culture flasks, 96 
well micro culture plates. 
METHODS: 
Maintenance of cell lines: 
Vero (African green monkey kidney cells), cell line were grown in 25 cm2 
tissue culture flasks containing DMEM medium supplemented with 10% FBS, 1% L- 
glutamine and 1% antibiotic-antimicotic solutions at 37ºC in CO2 incubator in an 
atmosphere of humidified 5% CO2 and 95% air. The cells were maintained by routine sub 
culturing in 25 cm2 tissue culture flasks. 
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Sub culturing process of cell lines: 
 The culture media from the flasks containing monolayer culture was aspirated and 
washed with sterile phosphate buffered saline (PBS). 
 To the flasks, 1 ml of 0.2% trypsin-EDTA solution was added and after few 
seconds it was aspirated and flask was kept in incubator 2-3 min. for detachment.  
 The flasks were removed from the incubator and gently tapped to detach all the 
adhering cells. The cell detachment was confirmed by observing under an inverted 
microscope (Nikon Eclipse TE 2000-5, Japan).  
 Once the cells were completely detached from the flasks, 2-3 ml of DMEM media 
containing 10% FBS was added and mixed well.  
 From the stock cell suspension, 1 x 105 viable cells/ml suspended in media were 
seeded in 25cm2 tissue culture flask containing about 4ml of fresh media and 
incubated until the flasks attained 60-70% confluence. 
Trypsinization: 
To obtain a single cell suspension from a monolayer culture, cells were dislodged from 
the culture flasks by trypsinization. 
 From a 60-70% confluent flask, the culture media was aspirated out using a 
micropipette. 
 Cells were washed with 3 ml of PBS to remove trace amount of media. 
 To each culture flask 1 ml of trypsin-EDTA was added and after few seconds it 
was aspirated and the flask was kept in the incubator for 3-4 min for cell 
detachment. 
 Culture flasks were observed under an inverted microscope (Nikon Eclipse, 
Japan) to ensure that cells were completely dislodged.  
 Trypsin activity was stopped by adding 2-3ml media containing 10% FBS.  
Seeding: 
Exponentially growing cell lines were harvested from 25cm2 Tissue culture flask and a 
stock cell suspension (5X106 cell/ml) was prepared.  
 A 96-well flat bottom tissue culture plate was seeded with 5 x103 cells in 0.1 ml of 
DMEM medium supplemented with 10% FBS and allowed to attach for 24hrs. 
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Preparation of drug dilutions: (serial dilution) 
 50mg/ml stock solution is prepared using 100% DMSO solution. From this stock 
solution various final concentrations (viz. 62.5, 125, 250 and 500 µg/ml) of test 
compound solution was prepared as follows: 
 500 µg/ml: 10 µL sol. was taken from stock and to this 990 µl media was added. 
 250 µg/ml: From 500 µg/ml 500 µl was taken and diluted with 500 µl with media. 
 125 µg/ml: From 250 µg/ml 500 µl was taken and diluted with 500 µl with media. 
 62.5 µg/ml: From 125 µg/ml 500 µl was taken and diluted with 500 µl with 
media. 
 After 24 hrs of incubation, cells were treated with 100 µl of test solutions from 
respective above stocks and the cells were incubated for 48 hrs. 
 The cells in the control group received only the medium containing the 0.5, 0.1 % 
DMSO.   
 Each treatment was performed in triplicates. 
SRB Assay:  
Principle  
Sulforhodamine B (SRB) assay was developed in 1990 is one of the most 
widely used methods for in vitro cytotoxicity screening. The assay relies on the ability of 
SRB to bind to protein components of cells that have been fixed to tissue-culture plates 
by trichloroacetic acid (TCA). SRB is a bright-pink amino xanthene dye with two 
sulfonic groups that binds to basic amino-acid residues under mild acidic conditions and 
dissociate under basic conditions. As the binding of SRB is stoichiometric, the amount of 
dye extracted from stained cells is directly proportional to the cell mass. 
Reagents: 
 10% (wt/vol) TCA 
 1% (vol/vol) acetic acid 
 0.057% (wt/vol) SRB (Sigma, cat. no. 86183) in 1% (vol/vol) acetic acid 
 10 mM unbuffered Tris base solution  
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Cell fixation and staining: 
 100 μl ice cold 10% (wt/vol) TCA was gently added to each well and the plates at 
4 °C for 1 h.  
 The plates were washed four times under slow-running tap water and excess water 
was removed by air drying the plates at room temperature. 
 100 μl 0.057% (W/V) SRB was added to the wells and incubated for 30 minutes 
at room temperature in dark. 
 The plates were then washed with 1% acetic acid to remove the unbound dye. The 
plates were air dried at room temperature. 
 200 μl of Tris base (10mM) was added to the wells and plates were places on 
shaker for 10 min. 
 Optical density was read at 540 nm in a ELISA plate reader. Percentage cell death 
was calculated (absorbance of control wells- absorbance of test wells / absorbance 
of control wells) x 100. 
 IC50 was calculated from the % cell death using GraphPad Prism 7® software. 
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RESULT AND DISCUSSION 
Drug Design: 
Docking and Interaction with Target Enzyme: 
Around hundred molecules, which were sketched using ChemSketch®, were 
docked against the M. tuberculosis, Glutamine synthetase I enzyme using Autodock 4® 
software. The molecules with best docking score and good interactions were selected and 
synthesized. 
Table 3. Docking and Interaction View 
SAMPLE 
CODE 
DOCKING 
SCORE 
(K.Cal/mol) 
DOCKING VIEW WITH 
Glutamine synthetase I  
(3zxr) 
INTERACTION VIEW 
Glutamine synthetase I 
(3zxr) 
 
 
BOB 
 
 
-6.26 
  
 
 
 
CIN 
 
 
 
-5.32 
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SAMPLE 
CODE 
DOCKING 
SCORE 
(K.Cal/mol) 
DOCKING VIEW WITH 
Glutamine synthetase I  
(3zxr) 
INTERACTION VIEW 
Glutamine synthetase I 
(3zxr) 
 
 
NIB 
 
 
-5.73 
 
 
 
 
 
 
 
 
 
 
 
OHB 
 
 
 
 
 
-4.18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHB 
 
 
 
 
 
-6.73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By docking with Glutamine synthetase enzyme the designed molecules showed 
better docking score. Among them BOB and PHB molecules have the lowest binding 
score of -6.26, and -6.73 Kcal/mol which is comparatively better than CIN, NIB, and 
OHB. 
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PREDICTION OF DRUG LIKENESS: 
Cheminformatics software Molinspiration® was employed to evaluate drug 
likeness. This tool is quick and easy to use. It is a software available online for 
calculation of important molecular properties like logP, polar surface area, number of 
hydrogen bond donors and acceptors and others, as well as prediction of bioavailability 
score for the compounds with best scoring. 
Table 4. Insilico prediction of Drug likeness results 
DRUG LIKENESS 
PARAMETERS 
SAMPLE CODE 
BOB CIN NIB OHB PHB 
Log P 4.36 3.46 2.64 2.64 2.23 
TPSA 47.38 38.15 83.97 58.38 58.38 
No. of non-Hydrogen atoms 22 16 17 15 15 
Molecular Weight 327.43 247.35 266.31 237.31 237.31 
No.of Hydrogen bond Acceptor 4 3 6 4 4 
No.of Hydrogen bond Donar Nil Nil Nil 1 1 
No.of Rule of 5 Violation Nil Nil Nil Nil Nil 
No. of rotatable bonds 5 3 3 2 2 
Molar Volume 275.97 206.19 202.11 186.79 186.79 
 
Where, 
TPSA is the Topological Polar Surface Area. 
From the above results all the compounds obeyed the Lipinski Rule of 5 and 
Rule of 7. Thus the proposed compounds which had good predictive activity and drug 
likeness properties were taken up for Toxicity prediction by using the OSIRIS® software.  
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PREDICTION OF TOXICITY: 
The docked molecules were tested for toxicity by Insilico Toxicity Prediction 
method using Osiris Property Explorer®. This online tool predicts physico-chemical and 
toxicological molecular properties. 
Table 5. Insilico Toxicity Prediction results 
TOXICITY  
RISK 
SAMPLE CODE 
BOB CIN NIB OHB PHB 
MUTAGENIC Nil Nil Nil Nil Nil 
TUMORIGENIC Nil Nil Nil Nil Nil 
IRRITANT Nil Nil Nil Nil Nil 
REPRODUCTIVE EFFECT Nil Nil Nil Nil Nil 
[-] – indicates absence of toxicity 
[+] – indicates presence of toxicity 
Snapshot of the Insilico Toxicity Predictions: 
Sample: BOB 
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Sample: CIN 
 
 
 
 
 
 
 
 
 
 
 
 
Sample: NIB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample: OHB 
 
 
 
 
 
 
 
 
 
 
 
 
RESULT AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai-03 61 
 
Sample: PHB 
 
 
 
 
 
 
 
 
 
None of the compounds BOB, CIN, NIB, OHB and PHB exhibited any kind of 
toxicity. These compounds will be synthesis by easy way of synthetic process (Schiff 
base synthesis). 
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SYNTHETIC EFFORTS: 
The synthesis was performed by the conventional method. The reaction was 
carried out by using 0.1 mole of 5-Amino-1,3,4-Thiadiazole-2-thiol, 0.1 mol of 
substituted aromatic aldehyde and ethanol acts as catalyst. The mixture was refluxed for 
about 4-5 hrs at 60 – 80oC. This leads to the formation of Schiff Base. 
Results of the Synthetic Scheme and Characterization: 
Sample Code: BOB 
 
 
 
 
PROFILE: 
IUPAC NAME:   5-({(E)-[4-(benzyloxy)phenyl]methylidene}amino)-1,3,4-thiadiazole- 
2-thiol 
Molecular Formula  : C16H13N3OS2 
Formula Weight  : 327.42392 
Composition   : C(58.69%) H(4.00%) N(12.83%) O(4.89%) S(19.59%) 
Appearance   : Pale Yellow colour powder  
Solubility   : Ethanol , Methanol and Chloroform 
Rf Value   : 0.56 
Melting Point   : 129-131oC 
Molar Refractivity  : 94.32 ± 0.5 cm3 
Molar Volume  : 248.4 ± 7.0 cm3 
Parachor   : 664.4 ± 8.0 cm3 
Index of Refraction  : 1.683 ± 0.05 
Surface Tension  : 51.1 ± 7.0 dyne/cm 
Density   : 1.31 ± 0.1 g/cm3 
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Polarizability   : 37.39 ± 0.5 10-24cm3 
Monoisotopic Mass  : 327.050002 Da 
Nominal Mass  : 327 Da 
Average Mass  : 327.4239 Da 
 
IR Spectrum: BOB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Table 6. Interpretation of IR Spectrum – BOB 
 
S.No. Functional Group Region Wave number (cm-1) 
1 Aromatic -C-H stretching 3132.17 cm-1 
2 Aliphatic –CH2- stretching 2885.30 cm-1 
3 -C=N- stretching 1604.66 cm-1 
4 -C-O-C- stretching 1257.50 cm-1 
5 -C-S-C- stretching 694.32 cm-1 
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LC-MS Spectrum: BOB 
Chromatogram: BOB 
 
 
Mass Spectrum: BOB 
 
Calculated Mass: 327.42 g/mol 
Actual Mass: 327.96 g/mol 
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H1 NMR Spectrum: BOB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Table 7. Interpretation of H1 NMR Spectrum – BOB 
 
S.No. Delta Value (𝛿) ppm Nature of peak No.of proton 
2 5.3 Triplet 2 
3 7.1-7.5 Multiplet 6 
4 8.6-8.7 Multiplet 4 
5 9.9 Singlet 1 
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Sample Code: CIN 
 
 
 
 
 
 
 
IUPAC NAME:  5-{[(1E,2E)-3-phenylprop-2-en-1-ylidene]amino}-1,3,4-thiadiazole- 
2-thiol 
Molecular Formula  : C11H9N3S2 
Formula Weight  : 247.33926 
Composition   : C(53.42%) H(3.67%) N(16.99%) S(25.93%) 
Appearance   : Yellow colour powder 
Solubility   : Ethanol, Methanol and Chloroform 
Rf Value   : 0.49 
Melting Point   : 115-117oC 
Molar Refractivity  : 72.44 ± 0.5 cm3 
Molar Volume  : 190.0 ± 7.0 cm3 
Parachor   : 507.0 ± 8.0 cm3 
Index of Refraction  : 1.687 ± 0.05 
Surface Tension  : 50.7 ± 7.0 dyne/cm 
Density   : 1.30 ± 0.1 g/cm3 
Polarizability   : 28.71 ± 0.5 10-24cm3 
Monoisotopic Mass  : 247.023787 Da 
Nominal Mass  : 247 Da 
Average Mass  : 247.3393 Da 
 
 
RESULT AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai-03 67 
 
IR Spectrum: CIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Table 8. Interpretation of IR Spectrum – CIN 
 
S.No. Functional Group Region Wave number (cm-1) 
1 Aromatic -C-H stretching 3132.17 cm-1 
2 Alkene –CH=CH- stretching 1689.52 cm-1 
3 -C=N- stretching 1604.66 cm-1 
4 -C-S-C- stretching 694.32 cm-1 
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LC-MS Spectrum: CIN 
Chromatogram: CIN 
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Mass Spectrum: CIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calculated Mass: 247.33 g/mol 
Actual Mass: 246.06 g/mol 
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H1 NMR Spectrum: CIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
    Table 9. Interpretation of H1 NMR Spectrum – CIN 
 
S.No. Delta Value (𝛿) ppm Nature of peak No.of proton 
1 6.8 Singlet 1 
2 7.2-7.7 Multiplet 7 
3 9.7 Singlet 1 
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Sample Code: NIB 
 
 
 
 
 
 
 
 
IUPAC NAME:   5- [(E) - (3-nitrophenyl) methylidene] amino}-1,3,4-thiadiazole- 
2-thiol 
Molecular Formula  : C9H6N4O2S2 
Formula Weight  : 266.29954 
Composition   : C(40.59%) H(2.27%) N(21.04%) O(12.02%) S(24.08%) 
Appearance   : Yellowish Green colour Powder 
Solubility   : Ethanol, Methanol and Chloroform 
Rf Value   : 0.53 
Melting Point   : 170-171oC 
Molar Refractivity  : 68.88 ± 0.5 cm3 
Molar Volume  :163.2 ± 7.0 cm3 
Parachor   : 475.2 ± 8.0 cm3 
Index of Refraction  : 1.786 ± 0.05 
Surface Tension  : 71.9 ± 7.0 dyne/cm 
Density   : 1.63 ± 0.1 g/cm3 
Polarizability   : 27.30 ± 0.5 10-24cm3 
Monoisotopic Mass  : 265.993215 Da 
Nominal Mass  : 266 Da 
Average Mass  : 266.2995 Da 
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IR Spectrum: NIB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Table 10. Interpretation of IR Spectrum – NIB 
 
S.No. Functional Group Region Wave number (cm-1) 
1 Aromatic –C-H- stretching 3124.45 cm 
2 -C=N- stretching 1612.37 cm 
3 -C-NO2 stretching 1481.22 cm 
4 -C-S-C- stretching 686.61 cm 
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LC-MS Spectrum: NIB 
Chromatogram: NIB 
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Mass Spectrum: NIB 
 
 
Calculated Mass: 266.29 g/mol 
Actual Mass: 267.03 g/mol 
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H1 NMR Spectrum: NIB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Table 11. Interpretation of H1 NMR Spectrum – NIB 
 
S.No. Delta Value (𝛿) ppm Nature of peak No.of proton 
1 5.5 Doublet 1 
2 7.1-8.3 Multiplet 4 
3 13.2 Singlet 1 
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Sample Code: OHB 
 
 
 
 
 
 
 
 
 
IUPAC NAMES :  2-{(E)-[(5-sulfanyl- 1,3,4-thiadiazol-2-yl) imino] methyl}phenol 
 
Molecular Formula  : C9H7N3OS2 
Formula Weight  : 237.30138 
Composition   : C(45.55%) H(2.97%) N(17.71%) O(6.74%) S(27.02%) 
Appearance   : Paale Yellow colour powder  
Solubility   : Ethanol, Methanol and Chloroform 
Rf Value   : 0.44 
Melting Point   : 146-148oC 
Molar Refractivity  : 64.07 ± 0.5 cm3 
Molar Volume  : 155.0 ± 7.0 cm3 
Parachor   : 435.4 ± 8.0 cm3 
Index of Refraction  : 1.764 ± 0.05 
Surface Tension  : 62.1 ± 7.0 dyne/cm 
Density   : 1.53 ± 0.1 g/cm3 
Polarizability   : 25.40 ± 0.5 10-24cm3 
Monoisotopic Mass  : 237.003052 Da 
Nominal Mass  : 237 Da 
Average Mass  : 237.3014 Da 
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IR Spectrum: OHB 
 
 
 
 
 
 
 
 
 
 
            Table 12. Interpretation of IR Spectrum - OHB 
S.No. Functional Group Region Wave number (cm-1) 
1 Alcoholic –OH stretching 3633.62 cm-1 
2 Aromatic –C-H- stretching 3132.17 cm-1 
3 -C=N- stretching 1604.66 cm-1 
4 -C-O- stretching 1280.64 cm-1 
5 -C-S-C- stretching 694.32 cm-1 
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LC-MS Spectrum: PHB 
Chromatogram: PHB 
 
Mass Spectrum: PHB 
 
Calculated Mass: 237.30 g/mol 
Actual Mass: 237.92 g/mol 
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H1 NMR Spectrum: OHB 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Table 13. Interpretation of H1 NMR Spectrum – OHB 
S.No. Delta Value (𝛿) ppm Nature of peak No.of proton 
1 7.1-7.2 Multiplet 4 
2 7.8 Singlet 1 
3 13.2 Triplet 2 
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Sample Code: PHB 
 
 
 
 
 
IUPAC NAMES:   4 - {(E) - [(5-sulfanyl- 1,3,4- thiadiazol-2-yl) imino]methyl}phenol 
Molecular Formula   : C9H7N3OS2 
Formula Weight  : 237.30138 
Composition   : C(45.55%) H(2.97%) N(17.71%) O(6.74%) S(27.02%) 
Appearance   : Pale Brown colour powder 
Solubility   : Ethanol, Methanol and Chloroform 
Rf Value   : 0.46 
Melting    : 174-176oC 
Molar Refractivity  : 64.07 ± 0.5 cm3 
Molar Volume  : 155.0 ± 7.0 cm3 
Parachor   : 435.4 ± 8.0 cm3 
Index of Refraction  : 1.764 ± 0.05 
Surface Tension  : 62.1 ± 7.0 dyne/cm 
Density   : 1.53 ± 0.1 g/cm3 
Polarizability   : 25.40 ± 0.5 10-24cm3 
Monoisotopic Mass  : 237.003052 Da 
Nominal Mass  : 237 Da 
Average Mass  : 237.3014 Da 
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IR Spectrum: PHB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Table 14. Interpretation of IR Spectrum – PHB 
 
S.No. Functional Group Region Wave number (cm-1) 
1 Alcoholic –OH 3625.91 cm-1 
2 Aromatic –C-H- stretching 3132.27 cm-1 
3 -C=N- stretching 1604.66 cm-1 
4 -C-O- stretching 1288.35 cm-1 
5 -C-S-C- 709.75 cm-1 
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LC-MS Spectrum: PHB 
Chromatogram: PHB 
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Mass Spectrum: PHB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calculated Mass: 237.30 g/mol 
Actual Mass: 237.95 g/mol 
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H1 NMR Spectrum: PHB 
 
 
 
 
 
Table 15. Interpretation of H1 NMR Spectrum – PHB 
 
S.No. Delta Value (𝛿) ppm Nature of peak No.of proton 
1 6.9 Singlet 1 
2 7.1-7.2 Multiplet 4 
3 13.2 Singlet 1 
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BIOLOGICAL EVALUATION: 
MABA REPORT OF THE SYNTHESISED COMPOUNDS: 
All the synthesized compounds were tested against  Mycobacterium tuberculosis 
(Vaccine strain, H37Rv strain): ATCC No- 27294. The compounds showed anti-
mycobacterial activity in a varying degree against the organism tested. The organism 
tested was susceptible to all the synthesized compounds and the minimum inhibitory 
concentration for the compounds varied between 12.5 and 3.125 mcg/ml. The data 
pertaining to these observations are presented in the table. Inhibition was compared with 
standard values. 
 
Standard values for the Anti-Tb test which was performed.  
 
 
 
Pyrazinamide- 3.125μg/ml  
Ciprofloxacin-3.125μg/ml  
Streptomycin- 6.25μg/ml 
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MIC Values for synthesized compounds 
 
 
 
 
 
 
 
Table 16. MIC values of Synthesized compounds by MABA 
Sample 
Code 
100 
μg/ml 
50 
μg/ml 
25 
μg/ml 
12.5 
μg/ml 
6.25 
μg/ml 
3.125 
μg/ml 
1.6 
μg/ml 
0.8 
μg/ml 
BOB S S S S S R R R 
CIN S S S S R R R R 
NIB S S S S S R R R 
OHB S S S S R R R R 
PHB S S S S S S R R 
 
S - Sensitive 
R- Resistance 
 From the results, all the synthesized molecules were compared with standard 
drugs such as Pyrazinamide- 3.125μg/ml, Ciprofloxacin-3.125μg/ml, Streptomycin- 
6.25μg/ml. Among them molecule PHB showed better MIC value of 3.125 μg/ml, and 
molecule BOB and NIB showed MIC values of 6.25 μg/ml. As comparing with standard 
drugs, the synthesized comounds PHB, BOB and NIB is more active. From the results 
only 4 compounds were selected for Acute Toxicity Study. 
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ACUTE ORAL TOXICITY STUDY: 
The active compounds from the MABA report BOB, NIB, OHB, PHB were chosen 
for acute oral toxicity study using albino mice (OECD guidelines(423)). After administration 
of molecules animals were observed for behavioral signs of toxicity like motor activity, 
tremor etc., and no significant toxic signs were observed during 14 days which was tabulated 
below. 
Table 17. Acute Oral Toxicity study  
S.No. PARAMETERS RESULTS 
1. Toxic signs Absent 
2. Pre-terminal deaths Nil 
3. Body weight No specific change 
4. Motor activity Normal 
5. Tremors Absent 
6. Convulsions Absent 
7. Straub reaction Absent 
8. Righting reflex Present 
9. Lacrimation and Salivation Normal 
10. Unusual vocalization Absent 
11. Sedation Absent 
12. Body temperature Normal 
13. Analgesia Absent 
14. Ptosis Absent 
15. Diarrhoea Absent 
16. Skin colour Normal 
17. Respiration Normal 
18. Scratching Absent 
19. Aggressiveness and restlessness Absent 
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The results of the acute toxicological studies revealed that the administration of 
4 molecules by oral route upto 2000mg/kg/b.w did not produce any mortality and it was 
tolerated. 
CYTOTOXICITY EVALUATION: 
The more active drugs BOB, NIB, OHB, PHB were chosen for Cytotoxicity study 
on Vero cell line and the results of Inhibitory concentration were tabulated below. 
Table 18. Cytotoxicity results 
Concentration 
(µg/ml) 
BOB NIB OHB PHB 
500 98.06 69.74 49.27 53.54 
250 72.52 57.38 35.84 31.23 
125 48.85 39.96 19.35 22.06 
64.5 26.06 20.83 7.78 9.65 
31.25 15.13 10.03 0.34 4.08 
IC50 from 
Prism 
121.5 201.9 472.9 456.2 
 
IC50 – Half maximal  inhibitory concentration 
The IC50 for Rifampicin is 113 µg/ml on vero cell line. The reported values of 
the compounds were compared with  standard drugs.  
Therefore as compared to Rifampicin the synthesized compounds were found to 
be more cytotoxic. 
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DISCUSSION 
From literature review the thiadiazole derivatives shows Anti-tubercular 
activity. The synthesized molecule BOB, CIN, NIB, OHB, PHB possesses thiadiazole 
nucles. According to the results of this work presence of thiol (-SH) group on 2nd position 
of 1,3,4 thiadiazole nucleus brings active compounds. In thiadiazole nucleus amino group 
in 5th position subjected for Schiff base formation with 5 aromatic aldehydes. 
Different aromatic aldehyde derivatives with thiadiazole nucleus shows 
different activity. Para substitution of hydroxyl (-OH) group in benzaldehyde shows 
better activity. Nitro substitution on 3rd position and Phenyl methoxy substitution in 4th 
position shows optimal activity. But Cinnamaldehyde shows less activity.  
summary  
and 
conclusion 
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SUMMARY 
 Glutamine synthetase I is a vital enzyme present in the cell wall of Mycobacterium 
tuberculosis H37Rv. It belongs to the Ligase family. 
 A database of 200 molecules with high prospects of inhibiting the target Glutamine 
synthetase I  were carefully chosen by making changes to the known hit molecules, here 
the thiadiazole nucleus was chosen. 
 The designed molecules were docked against the target chosen using AutoDock 4®. 
 Five molecules with good docking score [lower binding energy] and interactions were 
shortlisted for synthesis. 
 The selected molecules were subjected to toxicity prediction assessment by OSIRIS® 
property explorer developed by Acetilon Pharmaceuticals limited which is available 
online. The results are color coded as green color which predicts the drug likeness and 
possibly better activity. 
 The reaction condition were optimized, synthesized and labelled as BOB, CIN, NIB, 
OHB, PHB.  
 The characterization of the synthesized compounds was done using TLC, Melting point 
Infra-red, Mass spectrometric methods [LC-MS] and Nuclear Magnetic Resonance [H1 
NMR] spectroscopy methods. 
 All the Synthesized compounds exhibited molecular ion peak (M+) of varying intensities. 
 The final pure compounds were screened for Anti-mycobacterial activity by in vitro 
method called Microplate Alamar Blue Assay [MABA]. 
 The synthesized compounds showed sensitivity [Minimum inhibitory concentration] at 
3.125mcg/ml. The standard drugs Pyrazinamide, Ciprofloxacin and Streptomycin 
exhibited anti-mycobacterial activity at 3.125 mcg/ml, 3.125 mcg/ml and 6.25 mcg/ml 
concentrations respectively. This indicates that the synthesized compounds are as Potent 
as the standard drugs. 
 Based on the MABA report, Acute Oral Toxicity study were performed and observed that 
the administration of the synthesized molecules by oral route upto 2000mg/kg/b.w is safe. 
 The selected compounds showed IC50 Values of 121.5, 201.9, 472.9, 456.2 μg/ml 
respectively for BOB, NIB, OHB, PHB. Rifampicin showed IC50 value of 113 μg/ml. As 
compared with standard drug the synthesized molecules were found to be more cytotoxic. 
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CONCLUSION 
It is concluded that the synthesized compounds might effectively inhibit the 
chosen target Glutamine Synthetase I which is essential for the Mycobacterial 
tuberculosis. Further structural modifications of the synthesized compounds will aid in 
the development of potential molecule against the pathogen. 
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